European Psychiatry - Volume 33 - March 2016

111 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115 S107
Aims (1) To compare hospitalization rates of patients stabilized
on treatment with LAIs and CLZ. (2) To determine whether treat-
ment with LAIs and CLZ within CP can influence hospitalization
rates.
Methods Data were retrospectively collected from patients diag-
nosed with non-affective psychoses with FA between 2000 and
2014; 200 patients were then divided into three groups, according
to stabilized treatment regimen during the final year of observa-
tion: treatment as usual (TAU), CLZ, LAIs. hospitalization duration
(HSPD) and frequency (HSP) were calculated for each group.
Results Despite a major severity before assignment to either CLZ
or LAIs treatment, HSPD and HSP in both groups shifted below
those observed for the TAU arm. Patients who began treatment
with LAIs within the CP showed a highly significant decrease of
both HSPD and HSP (respectively 17.4 ±18 vs. 2.6 ± 8.2; Z = −2.856;
P < 0.005 and 1.1 ± 0.8 vs. 0.2± 0.5; Z = −3.115; P < 0.005). No signif-
icant changes in hospitalization rates were observed for subjects
who began treatment with LAIs after the CP.
Conclusions Our study confirms that treatment with either CLZ
or LAIs significantly impacts the course of psychotic disorders. The
data seem to suggest that LAIs and CLZ should be considered more
effective than conventional oral antipsychotics in the early-stages
of psychotic illness. The difference among treatments tends towane
beyond the CP, especially for LAIs.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC85
Metabolic syndrome in patients with
schizophrenia receiving long-term
treatment with lurasidone, quetiapine
XR, or risperidone
J. Newcomer Tocco Pikalov ∗ Zheng ucchiaro
A. Loebel
1 Florida Atlantic University Charles E. Schmidt College of Medicine,
N/A, Boca Raton, USA
2 Sunovion Pharmaceuticals Inc., N/A, Marlborough, USA
3 Sunovion Pharmaceuticals Inc., N/A, Fort Lee, USA
∗ Corresponding author.
Introduction Lurasidone has demonstrated low propensity for
metabolic disturbance in adult patients with schizophrenia in
short-term studies.
Objectives To evaluate metabolic syndrome occurrence during
long-term lurasidone treatment in patients with schizophrenia.
Aims To comparemetabolic syndrome rates with lurasidone ver-
sus other antipsychotic agents.
Methods Metabolic syndrome rates (as defined by the US
National Cholesterol Education Program-Adult Treatment Panel
III) were evaluated in adult patients with schizophrenia treated
with lurasidone in 2 long-term, active-controlled studies (queti-
apine XR or risperidone). In the quetiapine XR-controlled study,
patients completing a 6-week, double-blind, placebo-controlled,
fixed-dose trial of lurasidone (74mg/d or 148mg/d) or quetiapine
XR (600mg/d) continued on double-blind, flexibly dosed lurasi-
done (37–148mg/d) or quetiapine XR (200–800mg/d) for up to
12 months. In the risperidone-controlled study, patients received
double-blind, flexibly dosed lurasidone (37–111mg/d) or risperi-
done (2–6mg/d) for up to 12 months.
Results Among patients without metabolic syndrome at base-
line in the quetiapine XR-controlled study, 2.4% (2/84) of
lurasidone-treated patients and 7.4% (2/27) of quetiapine XR-
treated patients developed metabolic syndrome at month 12
(P =NS). Of patients without metabolic syndrome at baseline in the
risperidone-controlled study, 10.3% (12/117) and 23.2% (16/69) of
lurasidone- and risperidone-treated patients, respectively, devel-
oped metabolic syndrome at month 12 (P = 0.02).
Conclusions Long-term treatment with lurasidone was associ-
ated with lower rates of metabolic syndrome in patients with
schizophrenia compared to treatment with quetiapine XR or
risperidone.
Support Sunovion Pharmaceuticals Inc.
ClinicalTrials.gov identifiers NCT00789698, NCT00641745.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
FC86
Neurochemical and behavioral
sensitization to d-amphetamine in
healthy subjects measured with
[11C]-(+)-PHNO-PET
A. Popovic ∗, M. Bauer , L. Bartova , U. Sauerzopf ,
N. Praschak-Rieder , C. Rami-Mark , L. Nics , C. Philippe ,
M. Mitterhauser , W. Wadsak , S. Kasper , M. Willeit
1 Medical University of Vienna, Department of Psychiatry and
Psychotherapy, Vienna, Austria
2 Medical University of Vienna, Department of Clinical Pharmacology,
Vienna, Austria
3 Medical University of Vienna, Department of Nuclear Medicine,
Vienna, Austria
∗ Corresponding author.
Introduction It has been shown that patients with schizophre-
nia are super-sensitive towards dopamine-releasing agents such as
amphetamine. Here, we studied the effects of amphetamine sen-
sitization on amphetamine-induced dopamine release in healthy
subjects.
Objectives To measure d-amphetamine-induced dopamine
release as measured with the D2,3 agonist radioligand [11C]-(+)-
PHNO-PET via change in non-displacable binding potential (BPND )
and behavioral measures of d-amphetamine effects with drug
effects questionnaire (DEQ) and subjective states questionnaire
(SSQ).
Aims To study d-amphetamine-induced sensitization in healthy
subjects on a behavioral and neurochemical level with [11C]-(+)-
PHNO-PET in order to gain more knowledge on sensitization-
induced changes in the dopaminergic system.
Methods Twelve stimulant-naïve healthy male subjects under-
went three 90-min [11C]-(+)-PHNO-PET-scans and four oral
administrations of d-amphetamine. After a naïve baseline scan,
subjects underwent a PET scanwith previous ingestion of 0.4mg/kg
bodyweight of d-amphetamine 90–120minutes before scanning.
Subsequently, subjects were sensitized to d-amphetamine with
the same dose on two separate days. Thereafter, they underwent
another PET scanwith previous d-amphetamine ingestion. DEQand
SSQ were administered before, 60min, 90–120min, and 210min
after amphetamine ingestion.
Results We found significant sensitization effects on a behavioral
level and on a neurochemical level after four administrations of
amphetamine. Items of the SSQ, which showed significant sensi-
tization effects were “outgoing”, “energetic”, “lively”, “alert” and
“focused”.
Conclusions We were able to induce significant behavioral and
neurochemical sensitization in healthy humans, which were mea-
sured with [11C]-(+)-PHNO-PET for the first time. This sensitization
model will be useful for studying the neurobiology of schizophre-
nia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.